|
1.
|
Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May; 36(5):581-7.
|
|
|
|
|
2.
|
Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, Baab KT, Jarbadan NR, Irby R, Loughran TP. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood. 2010 Jan 7; 115(1):51-60.
|
|
|
|
|
3.
|
Nyland SB, Loughran TP. Putting HIV-1 apoptosis mediators to work against cancer: a killer job, with benefits. Cancer Biol Ther. 2009 Jan; 8(2):188-91.
|
|
|
|
|
4.
|
Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, Albert R, Loughran TP. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008 Oct 21; 105(42):16308-13.
|
|
|
|
|
5.
|
Ugen KE, Nyland SB. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy. Springer Semin Immunopathol. 2006 Nov; 28(3):281-7.
|
|
|
|
|
6.
|
Kothapalli R, Nyland SB, Kusmartseva I, Bailey RD, McKeown TM, Loughran TP. Constitutive production of proinflammatory cytokines RANTES, MIP-1beta and IL-18 characterizes LGL leukemia. Int J Oncol. 2005 Feb; 26(2):529-35.
|
|
|
|
|
7.
|
Nyland SB, Cao C, Bai Y, Loughran TP, Ugen KE. Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. J Acquir Immune Defic Syndr. 2003 Apr 1; 32(4):406-16.
|
|
|
|
|
8.
|
Nyland SB, Specter S, Ugen KE. Direct vs. indirect modulation of complex in vitro human retroviral infections by morphine. Adv Exp Med Biol. 2001; 493:49-58.
|
|
|
|
|
9.
|
Nyland SB, Specter S, Ugen KE. Morphine effects on HTLV-I infection in the presence or absence of concurrent HIV-1 infection. DNA Cell Biol. 1999 Apr; 18(4):285-91.
|
|
|
|
|
10.
|
Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, Nyland S, Lacy KE, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin Immunol. 1999 Jan; 90(1):100-7.
|
|
|
|
|
11.
|
Ugen KE, Nyland SB, Boyer JD, Vidal C, Lera L, Rasheid S, Chattergoon M, Bagarazzi ML, Ciccarelli R, Higgins T, Baine Y, Ginsberg R, Macgregor RR, Weiner DB. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 1998 Nov; 16(19):1818-21.
|
|
|
|
|
12.
|
Agadjanyan MG, Wang B, Nyland SB, Weiner DB, Ugen KE. DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1. Curr Top Microbiol Immunol. 1998; 226:175-92.
|
|
|
|
|
13.
|
Nyland SB, Specter S, Im-Sin J, Ugen KE. Opiate effects on in vitro human retroviral infection. Adv Exp Med Biol. 1998; 437:91-100.
|
|
|
|
|
14.
|
Noe SN, Nyland SB, Ugen K, Friedman H, Klein TW. Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp Med Biol. 1998; 437:223-9.
|
|
|
|
|
15.
|
Ugen KE, Boyer JD, Wang B, Bagarazzi M, Javadian A, Frost P, Merva MM, Agadjanyan MG, Nyland S, Williams WV, Coney L, Ciccarelli R, Weiner DB. Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial. Vaccine. 1997 Jun; 15(8):927-30.
|
|
|
|